Therapeutic Class Search: dermatological/antipsoriatic agents-interleukin-17 (il-17) antagonist, mc antibody
10 drug(s) found
Brand Name
| Therapeutic Class
| Dose/Strength | Status | Notes & Restrictions |
COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | SYRINGE 150 mg/mL | | |
COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | PEN INJECTOR 150 mg/mL | | |
COSENTYX PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | PEN INJECTOR 150 mg/mL | | |
COSENTYX SUBCUTANEOUS SYRINGE 150 MG/ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | SYRINGE 150 mg/mL | | |
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | SYRINGE 75 mg/0.5 mL | | |
SILIQ SUBCUTANEOUS SYRINGE 210 MG/1.5 ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | SYRINGE 210 mg/1.5 mL | | |
TALTZ AUTOINJECTOR (2 PACK) SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | AUTO-INJECTOR 80 mg/mL | | |
TALTZ AUTOINJECTOR (3 PACK) SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | AUTO-INJECTOR 80 mg/mL | | |
TALTZ AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | AUTO-INJECTOR 80 mg/mL | | |
TALTZ SYRINGE SUBCUTANEOUS SYRINGE 80 MG/ML Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | Dermatological Antipsoriatic Agents-Interleukin-17 (Il-17) Antagonist, Mc Antibody | SYRINGE 80 mg/mL | | |
Icon | Restriction | Definition |
| Additional details | Click for additional information |
| Age Restriction | Age Restriction |
| Generic Indicator | This is a generic drug. A generic drug is approved by the FDA
as having the same active ingredient as the brand name drug. Generally,
generic drugs cost less than brand name drugs. |
| Limited Access | Limited Access |
| MD | You may be taking these drugs on a long-term basis. Maintenance medications are generally those used to treat chronic conditions and long-term conditions. |
| Prior Authorization | The Plan requires you or your physician to get
prior authorization for certain drugs. This means that you will need to get
approval from The Plan before you fill your prescriptions. If you do not get
approval, The Plan may not cover the drug.
|
| Prior Authorization - New Starts | The Plan requires you or your physician to get
prior authorization for certain drugs. This means that you will need to get
approval from The Plan before you fill your prescriptions. If you do not get
approval, The Plan may not cover the drug. Prior authorization for this drug
applies to new starts only. |
| Quantity Limit | For certain drugs, The Plan limits the amount of the drug that will be covered. For example, “30 EA per 30 days” would mean your coverage of this drug is limited to 30 pills every 30 days, or 1 pill per day. |
| Step Therapy | In
some cases, The Plan requires you to first try certain drugs to treat your
medical condition before we will cover another drug for that condition. For
example, if Drug 1 and Drug 2 both treat your medical condition, The Plan may
not cover Drug 2 unless you try Drug 1 first. If Drug 1 does not work for you,
The Plan will then cover Drug 2. |